The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies

Recombinant oncolytic adenovirus injection (KD01)is an oncolytic vius product. Its main component is a conditionally replicativerecombinant human type 5 adenovirus, where part of the E3 region has been replaced with the gene encoding the tBid apoptoticprotein.AK104 is a humanized bispecific antibody co-targeting PD-1 (Programmed Cell Death Protein 1) and CTLA-4 (Cytotoxic T-Lymphocyte-Associated Antigen 4)-two key immune checkpoint receptors. It is designed as a novel tetrameric construct that preferentially binds to tumor-infiltrating lymphocytes (TILs) co-expressing PD-1 and CTLA-4 in the tu

Trial Details

NCT ID
NCT06552598
Phase
PHASE1
Sponsor
Tongji Hospital
Status
RECRUITING
Cancer Type
Endometrial Cancer Uterine Cancer
Interventions
  • KD01(the recombinant oncolytic adenovirus)
Locations (sample)
  • Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

  • Phase II: Reproductive-aged women with a strong desire to preserve fertility, who understand and accept potential risks (recommended age ≤ 40 years…
  • Eastern Cooperative Oncology Group (ECOG) Performance Status: 0 or 1.
  • Expected Survival: ≥ 3 months.
  • No major organ dysfunction, including but not limited to hematopoietic, cardiac, pulmonary, hepatic, and renal function.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Endometrial Cancer Uterine Cancer Trials on Trialify →